• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对 COVID-19 药物的现代审视:现有和潜在有效的药物。

A contemporary look at COVID-19 medications: available and potentially effective drugs.

机构信息

Department of Pharmaceutical Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.

出版信息

Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9188-9195. doi: 10.26355/eurrev_202009_22870.

DOI:10.26355/eurrev_202009_22870
PMID:32965013
Abstract

OBJECTIVE

There have been significant changes to the management of COVID-19 in recent months, including protocols and guidelines designed to prevent, diagnose, and treat the Novel Coronavirus (COVID-19). Several management options have been suggested and have since gained popularity, though we expect additional modifications to be made, as well as more new cases in the coming months, given a lack of definitive treatment and well-controlled experiments. This review highlights the available and potential treatments, along with the challenges associated with each.

MATERIALS AND METHODS

We conducted a comprehensive overview of all peer-reviewed studies, editorial comments, and letters to the editor based on a search in PubMed, Google Scholar, Web of Science, and Scopus. The following terms were used: "COVID-19," "SARS-CoV-2," "drug," "treatment," "medication," and "management." All searches were done between March and May 20, 2020.

RESULTS

There are several potential medications available for COVID-19, such as Interferon α (IFN-α), Teicoplanin, Ribavirin, Galidesivir, Lopinavir/Ritonavir, Chloroquine phosphate, Arbidol, Velpatasvir, Favipiravir, Ledipasvir, Remdesivir, Sofosbuvir, Darunavir, Qingfei Paidu Decoction (QPD), and Imatinib. However, we do not have a definitive and specific treatment yet.

CONCLUSIONS

We are expecting to have more cases in the coming weeks/months. Therefore, further research is needed to characterize the disease behavior, to find the absolute drug, and to refine the treatment.

摘要

目的

近几个月来,COVID-19 的管理发生了重大变化,包括旨在预防、诊断和治疗新型冠状病毒(COVID-19)的方案和指南。已经提出了几种管理选择,并且已经得到了普及,尽管我们预计会进行更多的修改,并且由于缺乏明确的治疗方法和良好的对照实验,在未来几个月内会出现更多的新病例。这篇综述强调了可用的和潜在的治疗方法,以及与每种方法相关的挑战。

材料和方法

我们在 PubMed、Google Scholar、Web of Science 和 Scopus 上进行了全面的文献检索,对所有同行评议的研究、社论评论和给编辑的信进行了综述。使用了以下术语:“COVID-19”、“SARS-CoV-2”、“药物”、“治疗”、“药物治疗”和“管理”。所有搜索均在 2020 年 3 月至 5 月 20 日之间进行。

结果

有几种潜在的药物可用于 COVID-19,例如干扰素 α(IFN-α)、替考拉宁、利巴韦林、加洛韦、洛匹那韦/利托那韦、磷酸氯喹、阿比多尔、韦帕他韦、法匹拉韦、利巴韦林、瑞德西韦、索非布韦、达鲁那韦、清肺排毒汤(QPD)和伊马替尼。但是,我们还没有明确和具体的治疗方法。

结论

我们预计在未来几周/几个月内会有更多的病例。因此,需要进一步研究来描述疾病行为,寻找绝对药物,并改进治疗方法。

相似文献

1
A contemporary look at COVID-19 medications: available and potentially effective drugs.对 COVID-19 药物的现代审视:现有和潜在有效的药物。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9188-9195. doi: 10.26355/eurrev_202009_22870.
2
[Chloroquine as a possible treatment for COVID-19].[氯喹作为新型冠状病毒肺炎的一种可能治疗方法]
Ned Tijdschr Geneeskd. 2020 Mar 11;164:D4936.
3
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物:临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
4
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
5
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2:洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
6
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].[疫情期间冠状病毒感染重症病例抗病毒治疗从经验医学到科学证据]
Med Intensiva (Engl Ed). 2020 Nov;44(8):509-512. doi: 10.1016/j.medin.2020.04.009. Epub 2020 Apr 22.
7
Psychopharmacology of COVID-19.新型冠状病毒肺炎的精神药理学。
Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18.
8
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
9
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.用于治疗新冠肺炎的药物:等待证据
Acta Med Port. 2020 Jul 1;33(7-8):500-504. doi: 10.20344/amp.13908. Epub 2020 May 4.
10
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19:系统评价。
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.

引用本文的文献

1
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.药物重新利用和天然产物对抗新型冠状病毒的有效性:一项综合综述。
Clin Pharmacol. 2024 Jan 4;16:1-25. doi: 10.2147/CPAA.S429064. eCollection 2024.
2
Preprocedural Viral Load Effects of Oral Antiseptics on SARS-CoV-2 in Patients with COVID-19: A Systematic Review.口腔消毒剂对新冠肺炎患者严重急性呼吸综合征冠状病毒2的术前病毒载量影响:一项系统评价。
Biomedicines. 2023 Jun 12;11(6):1694. doi: 10.3390/biomedicines11061694.
3
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.
新型冠状病毒肺炎(COVID-19)治疗方法:旧药新用的临床应用及基于靶点的药物发现的未来策略
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
4
Telemedicine Interventions as an Attempt to Improve the Mental Health of Populations during the COVID-19 Pandemic-A Narrative Review.远程医疗干预作为改善 COVID-19 大流行期间人群心理健康的尝试:叙事综述。
Int J Environ Res Public Health. 2022 Nov 13;19(22):14945. doi: 10.3390/ijerph192214945.
5
A computational study of metal-organic frameworks (MOFs) as potential nanostructures to combat SARS-CoV-2.作为潜在纳米结构对抗 SARS-CoV-2 的金属有机骨架(MOFs)的计算研究。
Sci Rep. 2022 Sep 20;12(1):15678. doi: 10.1038/s41598-022-19845-7.
6
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.索磷布韦联合利巴韦林治疗埃及 COVID-19 患者的疗效与标准治疗相比:一项随机对照试验。
J Med Life. 2022 Mar;15(3):350-358. doi: 10.25122/jml-2021-0175.
7
Non-nucleoside structured compounds with antiviral activity-past 10 years (2010-2020).具有抗病毒活性的非核苷结构化合物-过去 10 年(2010-2020)。
Eur J Med Chem. 2022 Mar 5;231:114136. doi: 10.1016/j.ejmech.2022.114136. Epub 2022 Jan 19.
8
Characteristics of Oral Manifestations in Symptomatic Non-Hospitalized COVID-19 Patients: A Cross-Sectional Study on a Sample of the Saudi Population.有症状的非住院COVID-19患者口腔表现的特征:对沙特人群样本的横断面研究。
Int J Gen Med. 2021 Dec 10;14:9547-9553. doi: 10.2147/IJGM.S331611. eCollection 2021.
9
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance.核苷类抗病毒前药瑞德西韦在治疗新型冠状病毒肺炎及其他疾病中的种间意义。
Anim Dis. 2021;1(1):15. doi: 10.1186/s44149-021-00017-5. Epub 2021 Sep 7.
10
Traditional Chinese Medicine, Qingfei Paidu Decoction and Xuanfei Baidu Decoction, Inhibited Cytokine Production NF-κB Signaling Pathway in Macrophages: Implications for Coronavirus Disease 2019 (COVID-19) Therapy.中药、清肺排毒汤和宣肺败毒汤抑制巨噬细胞中细胞因子产生及NF-κB信号通路:对2019冠状病毒病(COVID-19)治疗的启示
Front Pharmacol. 2021 Oct 26;12:722126. doi: 10.3389/fphar.2021.722126. eCollection 2021.